[미국특허]
Methods and implantable devices for treating supraventricular arrhythmias
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61N-001/00
출원번호
UP-0246165
(2005-10-11)
등록번호
US-7781402
(2010-09-13)
발명자
/ 주소
Ovsyshcher, Eli
Fleidervish, Ilya A.
Goldberg, Yuri
Zeldets, Vladimir
Gelvan, Dan
출원인 / 주소
Closed Loop Therapies Ltd.
대리인 / 주소
Fleit, Martin
인용정보
피인용 횟수 :
0인용 특허 :
38
초록▼
A medication, method and device for cardiac treatment are provided, in particular, for treating supraventricular arrhythmias. Specifically, a method is provided for treating supraventricular arrhythmias, using a therapeutically effective amount of a cholinergic receptor agonist, for example, acetylc
A medication, method and device for cardiac treatment are provided, in particular, for treating supraventricular arrhythmias. Specifically, a method is provided for treating supraventricular arrhythmias, using a therapeutically effective amount of a cholinergic receptor agonist, for example, acetylcholine. This device may be part of universal device which provides pacing and defibrillation. In particular, the present invention can be used to treat atrial fibrillation, atrial flutter and atrial tachycardia by a bolus injection of a rapidly hydrolysable cholinergic receptor agonist such as acetylcholine.
대표청구항▼
What is claimed is: 1. A method of treating supraventricular arrhythmias (SVA) in a subject in need thereof, the method comprising: administering to the subject a bolus injection of 0.001-20 mg per KG body weight of acetylcholine or an acetylcholine salt which has the ability to transiently modulat
What is claimed is: 1. A method of treating supraventricular arrhythmias (SVA) in a subject in need thereof, the method comprising: administering to the subject a bolus injection of 0.001-20 mg per KG body weight of acetylcholine or an acetylcholine salt which has the ability to transiently modulate at least one electrical property of at least a portion of atrial cells thereby treating the supraventricular arrhythmia in the subject. 2. The method of claim 1, wherein said SVA is atrial fibrillation. 3. The method of claim 1, wherein said SVA is atrial tachycardia. 4. The method of claim 1, wherein said SVA is atrial flutter. 5. The method of claim 1, wherein said acetylcholine or acetylcholine salt is formulated for intravascular, intramuscular and/or intracardiac administration. 6. The method of claim 5, wherein said intracardiac administration is into a chamber of a heart. 7. The method of claim 5, wherein said intracardiac administration is effected via the right atrium, left atrium, right ventricle, and/or left ventricle. 8. The method of claim 5, wherein said intravascular administration is effected via a vein and/or an artery. 9. The method of claim 8, wherein said artery is a coronary artery and/or a pulmonary artery. 10. The method of claim 8, wherein said vein is a peripheral vein, a central vein and/or a coronary sinus. 11. The method of claim 10, wherein said central vein is a superior vena cava and/or an inferior vena cava. 12. The method of claim 1, wherein said administration is effected using a catheter, a cannula, a needle, syringe and/or a pump. 13. The method of claim 12, wherein said catheter is a part of a pacing lead-catheter. 14. The method of claim 12, wherein said catheter comprises a lumen for drug delivery. 15. The method of claim 1, wherein said acetylcholine salt is selected from the group consisting of acetylcholine chloride, acetylcholine bromide, acetylcholine iodide. 16. The method of claim 1, wherein said bolus injection of acetylcholine or acetylcholine salt is from a range of 0.02-0.4 mg per kg body weight. 17. The method of claim 1, wherein said acetylcholine or acetylcholine salt is incapable of modulating at least one electrical property of ventricular cells. 18. The method of claim 1, wherein said at least one electrical property is selected from the group consisting of refractoriness, excitability, speed of excitation propagation, focal automaticity, and spatial pattern of excitation. 19. The method of claim 1, wherein said acetylcholine or acetylcholine salt has the ability to transiently modulate said at least one electrical property of said at least a portion of atrial cells for no more than 5 seconds. 20. The method of claim 1 wherein said cholinergic receptor is a muscarinic m2 receptor. 21. The method according to claim 1 wherein the quantity of said acetylcholine or acetylcholine salt in said bolus is such that the concentration acetylcholine or acetylcholine salt in the blood after injection will fall to near zero in seconds, thereby avoiding the proarrhythmic effects of the acetylcholine or acetylcholine salt.
David B. Masters, Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Johnson, Randolph Mellus; Theeuwes, Felix; Gillis, Edward M.; Litmanovitz, Dana; Laidlaw, Barbara; Brown, James; Culwell, John; Filice, James A.; Wickman, Peter; Yum, Su-Il; Poutiatine, Andrew; Dinka, Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Belardinelli Luiz ; Olsson Ray ; Baker Stephen ; Scammells Peter J.,AUX ; Milner Peter G. ; Pfister Jurg R., N.sup.6 -(epoxynorborn-2-yl) adenosines as A.sub.1 adenosine receptor agonists.
Arzbaecher Robert C. (Chicago IL) Bump Thomas E. (Chicago IL) Yurkonis Charles E. (Mt. Prospect IL) Bloem David R. (Evergreen Park IL), Pharmacologic atrial defibrillator and method.
Rahme, Marc Mounir, Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.